Nuvalent Shares Surge 39% as GSK Strikes $10.6 Billion Cancer Drug Deal

Nuvalent shares surged nearly 39% in premarket trading after British pharmaceutical giant GSK agreed to buy the U.S. cancer drugmaker for $10.6 billion, a major bet on lung cancer treatments that could help reshape GSK’s oncology pipeline before a looming revenue challenge later this decade.

The all-cash deal values Nuvalent at about $124 per share, representing a roughly 40% premium to its last closing price. The transaction gives GSK access to two late-stage lung cancer therapies currently under U.S. Food and Drug Administration review, both of which the company believes could become significant commercial products if approved.

GSK shares slipped in London after the announcement, reflecting investor caution over the size of the acquisition and the cost of buying assets that still face regulatory and commercial tests. Nuvalent investors, however, reacted strongly to the cash premium, sending the stock sharply higher as the market priced in the takeover value.

GSK makes a bigger oncology move

The deal marks one of GSK’s largest acquisitions in years and a clear shift toward a more aggressive pipeline-building strategy. The company has spent recent years focusing on smaller transactions, but the Nuvalent agreement signals a broader push to expand in cancer medicines, particularly in targeted lung cancer treatments.

Nuvalent is a clinical-stage biotech company focused on precisely targeted oncology therapies for patients whose cancers are driven by specific genetic mutations. Its lead programs are designed for forms of non-small cell lung cancer, the most common type of lung cancer, where patients can carry alterations involving genes such as ROS1, ALK or HER2.

The two main assets in the deal are zidesamtinib, also known as NVL-520, and neladalkib, also known as NVL-655. Zidesamtinib targets ROS1-positive non-small cell lung cancer, while neladalkib targets ALK-positive disease. Both have received FDA Breakthrough Therapy and Orphan Drug designations, according to GSK’s announcement.

GSK said zidesamtinib has a target FDA decision date of September 18, 2026, while neladalkib has a target decision date of November 27, 2026. If approved, the company expects both drugs could launch in 2026 and provide new treatment options for patients with genetically defined forms of lung cancer.

Nuvalent deal targets GSK’s future revenue gap

The timing of the acquisition matters. GSK is preparing for pressure from the expected loss of exclusivity for dolutegravir, one of its most important HIV medicines, during the 2028 to 2030 period. That patent cliff has kept investor attention firmly on whether GSK can bring enough new products to market to offset future revenue erosion.

By acquiring Nuvalent, GSK gains two drugs that are already in late-stage development and under FDA review, rather than earlier research assets that could take years to prove themselves. The company said the transaction is expected to contribute to revenue growth from 2027, support core operating profit in 2027, and become accretive to core earnings per share in 2029, including synergies and portfolio reprioritisation.

GSK also said the acquisition should strengthen its ability to navigate the dolutegravir loss-of-exclusivity period while supporting its ambition to deliver more than £40 billion in sales by 2031. That makes Nuvalent not only an oncology acquisition but also a defensive move against a future earnings gap.

The deal includes a third asset, NVL-330, a potential HER2 inhibitor currently in Phase 1 trials for HER2-altered non-small cell lung cancer. GSK will also gain Nuvalent’s preclinical portfolio, giving it a wider base for future targeted cancer drug development.

For GSK, the attraction is the possibility of entering lung cancer with multiple programs at once. Lung cancer remains one of the most commercially important cancer markets, and targeted therapies have become a central part of treatment for patients whose tumours carry specific genetic drivers.

Valuation debate follows 39% Nuvalent jump

The market reaction underlines the split between Nuvalent shareholders and GSK investors. Nuvalent’s surge reflects the immediate cash premium. GSK’s weaker share move suggests investors are weighing the risks of paying a high price before the acquired drugs receive final approval and begin generating revenue.

Analysts cited in the deal coverage noted that the acquisition makes strategic sense because it adds late-stage, clinically de-risked oncology assets to GSK’s portfolio. But questions remain over whether zidesamtinib and neladalkib can achieve the kind of blockbuster sales needed to justify the price tag.

One estimate cited before the deal suggested the two lead drugs could generate combined annual revenue of around $823 million by financial year 2029 if approved. That figure would be meaningful, but the broader investor debate is whether the assets can grow beyond that level and become large enough to materially change GSK’s growth profile.

The acquisition will be funded mainly with new and existing debt facilities plus cash. GSK said it does not expect the deal to affect its credit rating and confirmed there is no change to its 2026 full-year guidance for core operating profit and core earnings-per-share growth. The company also reaffirmed its expected 70p dividend for 2026.

Completion remains subject to customary conditions, including the tender of a majority of Nuvalent’s outstanding shares and the expiration or termination of the applicable U.S. antitrust waiting period. If completed, GSK expects to acquire the remaining shares through a second-step merger under Delaware law at the same cash price.

The deal lands during a busy period for biotech mergers and acquisitions, as large pharmaceutical companies look for growth before patent cliffs hit older blockbuster drugs. For Nuvalent, the offer delivers a substantial premium before two important FDA decisions. For GSK, the acquisition is a high-stakes bet that targeted lung cancer medicines can help drive the next phase of growth.